Vascular Endothelial Growth Factor Immunoneutralization Plus Paclitaxel Markedly Reduces Tumor Burden and Ascites in Athymic Mouse Model of Ovarian Cancer
- 1 November 2002
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 161 (5) , 1917-1924
- https://doi.org/10.1016/s0002-9440(10)64467-7
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- Targeting Vascular Endothelial Growth Factor Blockade: Ascites and Pleural Effusion FormationThe Oncologist, 2000
- Inhibition of Liver Metastasis of Human Pancreatic Carcinoma by Angiogenesis Inhibitor TNP‐470 in Combination with CisplatinJapanese Journal of Cancer Research, 1998
- The TaxoidsDrugs, 1998
- The role of neutrophils and platelet-activating factor in mediating experimental pancreatitisGastroenterology, 1996
- Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1996
- Influence of an anti‐angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapyInternational Journal of Cancer, 1995
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991
- New Natural Products in Cancer ChemotherapyThe Journal of Clinical Pharmacology, 1990